Peptide Based Cardiovascular Therapeutics Market by Manufacturers, Types, Regions and Application Research Report Forecast to 2022

Rockville, US, 2018-Jan-15 — /EPR Network/ —  Fact.MR has recently added a new report to its vast online database. This research study is titled as “Peptide Based Cardiovascular Therapeutics Market Report” which presents an in-depth study about the production, consumption, market volume, revenue (million USD) and market share across different geographical regions.

Request For Sample Report https://www.factmr.com/connectus/sample?flag=S&rep_id=191

Cardiovascular disease is the leading cause of mortality and morbidity all over the world. In the past, the development of peptides as therapeutic agents had been avoided by pharmaceutical industry due to their low stability, rate of degradation and poor delivery. However, in recent times, resurgence has taken place in the field of peptides as therapeutics. Economic factors such as increasing healthcare expenditure and increasing FDI in emerging economies are expected to drive the market of peptide based cardiovascular therapeutics. Additionally, increasing prevalence of cardiovascular disorders, emergence of prominent pharmaceutical and biotech companies and strong R&D in the development of new peptides are fuelling the market growth. However, various factors such as increasing costs of commercialization, rapid metabolism of peptide drugs and regulatory conditions are expected to hamper market growth.

Therapeutic peptides are used in the treatment of cardiovascular disorders that are a leading cause of mortality and morbidity throughout the world. Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. Such type of covalent chemical bonds are formed when the carboxyl group of one amino acid reacts with the amino group of another. Peptides are differentiated from proteins on the basis of size, and peptides contain 50 amino acids or less approximately.

4 Forecast Highlights on Global Peptide Based Cardiovascular Therapeutics Market

1.    As per the forecast of Fact.MR, the eptifibatide segment is slated to touch a value of nearly US$ 600 Mn in the year 2022. This represents a robust CAGR growth during the assessment period of 2017-2022. The eptifibatide segment is estimated to account for nearly one-third of the revenue share of the drug segment by the year 2017 end and is expected to gain in market share by the year 2022 end.

2.    As per the forecast of Fact.MR, the retail pharmacies segment will reach a value of nearly US$ 425 Mn in the year 2017. This represents a robust CAGR growth during the forecast period. The retail pharmacies segment is estimated to account for more than one-third of the revenue share of the distribution channel segment in the year 2017 end and is expected to gain market share by the end of the year 2022.

3.    As per the forecast of Fact.MR, North America peptide based cardiovascular therapeutics market is expected to register a robust CAGR over the forecast period and to be valued at nearly US$ 830 Mn by 2022 end.

4.    As perFact.MR forecasts, US peptide based cardiovascular therapeutics market is estimated to account for 88.6% revenue share of the global peptide based cardiovascular therapeutics market by 2017 end and is expected to gain market share by 2022 over 2017

North America Market Set to Dominate the Global Peptide Based Cardiovascular Therapeutics Market in Terms of Revenue

The market in North America is set to dominate the global peptide based cardiovascular therapeutics market in terms of value and this trend is projected to sustain itself throughout the assessment period. North America peptide based cardiovascular therapeutics market is the most attractive market, growing at a robust CAGR over the assessment period.

Bivalirudin Segment Poised to Touch a Value of Nearly US$ 1,360 Mn in 2022

As per the forecast of Fact.MR, the bivalirudin segment is expected to reach a value of nearly US$ 1,360 Mn in the year 2022. This represents a robust CAGR during the forecast period of 2017-2022. Bivalirudin segment is expected to account for more than two-third of the revenue share of the drug segment by the year 2017 and is expected to lose market share by the end of the year 2022.

Browse Full Report with TOC @ https://www.factmr.com/report/191/peptide-based-cardiovascular-therapeutics-market

Hospital Pharmacies Segment to exhibit a CAGR of 8.9% During the Assessment Period

As per the forecast of Fact.MR, the hospital pharmacies segment is slated to touch a figure of nearly US$ 960 Mn in the year 2022. This represents a CAGR of 8.9% during the assessment period from 2017 till the year 2022. This segment is expected to lose market share by the end of the year 2022. The hospital pharmacies segment is expected to account for more than half of the revenue share of the distribution channel segment by the year 2017.

Competition Tracking

The report also profiles companies that are expected to remain active in the expansion of global peptide based cardiovascular therapeutics market through 2022, which include AstraZeneca, plc, Corden Pharma GmbH, Ipsen S.A, Merck & Co., Inc., Pfizer Inc, Apotex Holdings, Inc., Dr. Reddy’s Laboratories Limited, Fresenius Kabi USA, LLC, Novetide Ltd and Amneal Pharmaceuticals LLC.

Check Discount @ https://www.factmr.com/connectus/sample?flag=D&rep_id=191

About Fact.MR        
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Healthcare market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/

Matched content

Editor’s pick

Express Press Release Distribution